Com. Kessler on drug prices
"There are drugs, to be honest with you, that I do have concerns about their price -- it's an access question," FDA Commissioner Kessler told the House Appropriations/Agriculture Subcommittee March 24. Prodded by Rep. Durbin (D-Ill.), Kessler said FDA could work on approving drugs more quickly, "but unless people have access to them, what good is it." The issue has "global implications," he added, asking, "who can afford AZT on the continent of Africa?" Nonetheless, Kessler stressed that he wants to preserve FDA's focus on safety and efficacy and "to stay away from economic issues".
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth